{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:01:00Z","timestamp":1793145660944,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.afos.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T13:48:46Z","timestamp":1710596926000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Asia-Pacific consensus on long-term and sequential therapy for osteoporosis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-4861","authenticated-orcid":false,"given":"Ta-Wei","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-7566","authenticated-orcid":false,"given":"Hsuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-5623","authenticated-orcid":false,"given":"Chien-An","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6265-5155","authenticated-orcid":false,"given":"Chun-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8140","authenticated-orcid":false,"given":"Eugene","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-1689","authenticated-orcid":false,"given":"Joon-Kiong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-3667","authenticated-orcid":false,"given":"Swan Sim","family":"Yeap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-9144","authenticated-orcid":false,"given":"Ching-Lung","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-7511","authenticated-orcid":false,"given":"Natthinee","family":"Charatcharoenwitthaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-9805","authenticated-orcid":false,"given":"Unnop","family":"Jaisamrarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8348-0369","authenticated-orcid":false,"given":"Vilai","family":"Kuptniratsaikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0553-4779","authenticated-orcid":false,"given":"Rong-Sen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4191-2183","authenticated-orcid":false,"given":"Sung-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-1487","authenticated-orcid":false,"given":"Akira","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7660-5562","authenticated-orcid":false,"given":"Satoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-9747","authenticated-orcid":false,"given":"Julie","family":"Li-Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-634X","authenticated-orcid":false,"given":"Seng Bin","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-2243","authenticated-orcid":false,"given":"Ding-Cheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-0266","authenticated-orcid":false,"given":"Wai Sin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8360-5608","authenticated-orcid":false,"given":"Hou","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1236-1546","authenticated-orcid":false,"given":"Jung-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-7409","authenticated-orcid":false,"given":"Shih-Te","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7394-4016","authenticated-orcid":false,"given":"Hai-Hua","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9756-5037","authenticated-orcid":false,"given":"Yin-Fan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-5755","authenticated-orcid":false,"given":"Fang-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8528-1566","authenticated-orcid":false,"given":"Keh-Sung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2921-3742","authenticated-orcid":false,"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2899-9840","authenticated-orcid":false,"given":"Fernando","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-931X","authenticated-orcid":false,"given":"Francisco Javier","family":"Nistal Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4507-9691","authenticated-orcid":false,"given":"Huipeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6845-1260","authenticated-orcid":false,"given":"Kyu Ri","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-5431","authenticated-orcid":false,"given":"Kwang-Kyoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0179-4386","authenticated-orcid":false,"given":"Yoon-Sok","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-8443","authenticated-orcid":false,"given":"Manju","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-4417","authenticated-orcid":false,"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-9587","authenticated-orcid":false,"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6135-4257","authenticated-orcid":false,"given":"Fen Lee","family":"Hew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8382-5080","authenticated-orcid":false,"given":"Lan T.","family":"Ho-Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3246-6281","authenticated-orcid":false,"given":"Tuan Van","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-8056","authenticated-orcid":false,"given":"Van Hy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-9982","authenticated-orcid":false,"given":"Sarath","family":"Lekamwasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2300-7755","authenticated-orcid":false,"given":"Dipendra","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-8778","authenticated-orcid":false,"given":"Sanjay","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-4792","authenticated-orcid":false,"given":"Chung-Hwan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1979-6160","authenticated-orcid":false,"given":"Jawl-Shan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-2053","authenticated-orcid":false,"given":"Chih-Hsing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.afos.2018.03.003","article-title":"An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study","volume":"4","author":"Cheung","year":"2018","journal-title":"Osteoporos Sarcopenia"},{"issue":"3","key":"10.1016\/j.afos.2024.02.001_bib2","doi-asserted-by":"crossref","first-page":"Itc17","DOI":"10.7326\/AITC201708010","volume":"167","author":"Ensrud","year":"2017","journal-title":"Osteoporosis. Ann Intern Med"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.afos.2018.06.001","article-title":"The development of Taiwan fracture liaison service network","volume":"4","author":"Chang","year":"2018","journal-title":"Osteoporos Sarcopenia"},{"issue":"9","key":"10.1016\/j.afos.2024.02.001_bib4","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-020-05378-0","article-title":"Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review","volume":"31","author":"Cornelissen","year":"2020","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.afos.2024.02.001_bib5","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0025-6196(11)61093-8","article-title":"Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis","volume":"82","author":"Kothawala","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.afos.2024.02.001_bib6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ejim.2013.03.012","article-title":"Osteoporosis treatment: focus on safety","volume":"24","author":"Reid","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11657-021-00944-3","article-title":"Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center","volume":"16","author":"Bareli","year":"2021","journal-title":"Arch Osteoporosis"},{"issue":"5","key":"10.1016\/j.afos.2024.02.001_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.20945\/2359-3997000000564","article-title":"The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence","volume":"66","author":"Chandran","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.afos.2024.02.001_bib9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41574-023-00866-9","article-title":"Long-term and sequential treatment for osteoporosis","volume":"19","author":"Foessl","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/clinem\/dgad496","article-title":"Sequential therapy for the long-term treatment of postmenopausal osteoporosis","volume":"109","author":"Ramchand","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.afos.2024.02.001_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1759720X18785539","article-title":"Improving drug adherence in osteoporosis: an update on more recent studies","volume":"10","author":"Jaleel","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"10.1016\/j.afos.2024.02.001_bib12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1524-4733.2009.00687.x","article-title":"Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence","volume":"13","author":"Hiligsmann","year":"2010","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.afos.2024.02.001_bib13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jval.2010.11.010","article-title":"A meta-analysis of osteoporotic fracture risk with medication nonadherence","volume":"14","author":"Ross","year":"2011","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jval.2011.11.030","article-title":"Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review","volume":"15","author":"Muller","year":"2012","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.afos.2024.02.001_bib15","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1111\/jgs.17381","article-title":"Cost-effectiveness of secondary fracture prevention intervention for Medicare beneficiaries","volume":"69","author":"Nayak","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.afos.2024.02.001_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.afos.2024.02.001_bib17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jfma.2023.01.007","article-title":"Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update","volume":"122","author":"Tai","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.afos.2023.06.001","article-title":"Summary of the Thai osteoporosis foundation (TOPF) clinical practice guideline on the diagnosis and management of osteoporosis 2021","volume":"9","author":"Charatcharoenwitthaya","year":"2023","journal-title":"Osteoporos Sarcopenia"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.afos.2023.06.002","article-title":"A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022","volume":"9","author":"Ong","year":"2023","journal-title":"Osteoporos Sarcopenia"},{"issue":"3","key":"10.1016\/j.afos.2024.02.001_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1756-185X.2011.01626.x","article-title":"Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines","volume":"14","author":"Li-Yu","year":"2011","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.afos.2024.02.001_bib21","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"issue":"10117","key":"10.1016\/j.afos.2024.02.001_bib22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.afos.2024.02.001_bib23","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.afos.2024.02.001_bib24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.afos.2024.02.001_bib25","first-page":"1","article-title":"The clinician's guide to prevention and treatment of osteoporosis","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.afos.2024.02.001_bib26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 Year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.afos.2024.02.001_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2024.02.001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116480","article-title":"Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: the prospective VICTOR study","volume":"162","author":"Kobayakawa","year":"2022","journal-title":"Bone"},{"issue":"9999","key":"10.1016\/j.afos.2024.02.001_bib29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.afos.2024.02.001_bib30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.afos.2024.02.001_bib31","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 Months of alendronate after 18 Months of abaloparatide or Placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.afos.2024.02.001_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jbm4.10054","article-title":"Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial","volume":"2","author":"Niimi","year":"2018","journal-title":"JBMR Plus"},{"issue":"9","key":"10.1016\/j.afos.2024.02.001_bib33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.eprac.2021.05.012","article-title":"Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis","volume":"27","author":"Kocjan","year":"2021","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.afos.2024.02.001_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"10102","key":"10.1016\/j.afos.2024.02.001_bib35","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.afos.2024.02.001_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"10","key":"10.1016\/j.afos.2024.02.001_bib37","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/clpt.2011.62","article-title":"Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan","volume":"90","author":"Lin","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.afos.2024.02.001_bib40","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.afos.2024.02.001_bib42","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1210\/jc.2019-00924","article-title":"Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use","volume":"104","author":"Lyu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.afos.2024.02.001_bib43","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.afos.2024.02.001_bib44","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.afos.2024.02.001_bib45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.11005\/jbm.2021.28.1.51","article-title":"Zoledronic acid after treatment with denosumab is associated with bone loss within 1 year","volume":"28","author":"Kadaru","year":"2021","journal-title":"J Bone Metab"},{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jbmr.4737","article-title":"The effect of zoledronic acid on bone microarchitecture and strength after denosumab and teriparatide administration: DATA-HD study extension","volume":"38","author":"Ramchand","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","article-title":"The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial","volume":"35","author":"Ramchand","year":"2024","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.afos.2024.02.001_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","article-title":"Duration of bisphosphonate drug holidays and associated fracture risk","volume":"58","author":"Curtis","year":"2020","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.afos.2024.02.001_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.11005\/jbm.2015.22.4.151","article-title":"Medication related osteonecrosis of the jaw: 2015 position statement of the Korean society for bone and mineral research and the Korean association of oral and maxillofacial surgeons","volume":"22","author":"Kim","year":"2015","journal-title":"J Bone Metab"},{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on osteonecrosis of the jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J Bone Miner Metabol"},{"issue":"5","key":"10.1016\/j.afos.2024.02.001_bib53","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.afos.2024.02.001_bib54","series-title":"Pathology and management of medication-related osteonecrosis of the jaw: Committee on osteonecrosis of the jaw: position paper 2023 (Japanese language)","year":"2023"},{"issue":"6","key":"10.1016\/j.afos.2024.02.001_bib55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00774-023-01458-3","article-title":"Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey","volume":"41","author":"Taguchi","year":"2023","journal-title":"J Bone Miner Metabol"},{"issue":"9","key":"10.1016\/j.afos.2024.02.001_bib56","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1359\/jbmr.080418","article-title":"Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users","volume":"23","author":"Curtis","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.afos.2024.02.001_bib57","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s00198-017-4215-9","article-title":"Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk","volume":"28","author":"Mignot","year":"2017","journal-title":"Osteoporos Int"},{"issue":"26","key":"10.1016\/j.afos.2024.02.001_bib58","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a Placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.afos.2024.02.001_bib59","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bjoms.2021.10.004","article-title":"Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series","volume":"60","author":"Yoshiga","year":"2022","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"8","key":"10.1016\/j.afos.2024.02.001_bib60","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2013-4119","article-title":"The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene","volume":"99","author":"Chiu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.afos.2024.02.001_bib61","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.afos.2024.02.001_bib62","article-title":"A brief review and clinical evidences of teriparatide therapy for atypical femoral fractures associated with long-term bisphosphonate treatment","volume":"9","author":"Gao","year":"2022","journal-title":"Front Surg"},{"issue":"8","key":"10.1016\/j.afos.2024.02.001_bib63","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00198-023-06768-w","article-title":"The effect of teriparatide on fracture healing after atypical femoral fracture: a systematic review and meta-analysis","volume":"34","author":"Byun","year":"2023","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.afos.2024.02.001_bib64","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical Femur fractures: a systematic review and recommendations from the European Calcified Tissue Society","volume":"105","author":"van de Laarschot","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2024.02.001_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116216","article-title":"Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: a nationwide population study","volume":"154","author":"Tai","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.afos.2024.02.001_bib66","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jfma.2023.04.004","article-title":"Refracture risk and all-cause mortality after vertebral fragility fractures: anti-osteoporotic medications matter","volume":"122","author":"Tai","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"10","key":"10.1016\/j.afos.2024.02.001_bib67","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00198-023-06845-0","article-title":"Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients","volume":"34","author":"Tsai","year":"2023","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.afos.2024.02.001_bib68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.12809\/hkmj198337","article-title":"Hip fractures are preventable: a proposal for osteoporosis screening and fall prevention in older people","volume":"26","author":"Kwok","year":"2020","journal-title":"Hong Kong Med J"},{"issue":"5","key":"10.1016\/j.afos.2024.02.001_bib69","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jbmr.3381","article-title":"The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: Economic evaluation of the SCOOP study","volume":"33","author":"Turner","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.afos.2024.02.001_bib70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11657-021-01020-6","article-title":"Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan","volume":"16","author":"Johnson","year":"2021","journal-title":"Arch Osteoporosis"},{"key":"10.1016\/j.afos.2024.02.001_bib71","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jfma.2023.07.018","article-title":"Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: a population-based national claims database analysis","volume":"122","author":"Wang","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib72","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","article-title":"Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture","volume":"49","author":"Hiligsmann","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.afos.2024.02.001_bib73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","article-title":"An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis","volume":"39","author":"Li","year":"2021","journal-title":"Pharmacoeconomics"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240552552400030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240552552400030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:10:37Z","timestamp":1713193837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240552552400030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S240552552400030X"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2024.02.001","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asia-Pacific consensus on long-term and sequential therapy for osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}